RxDoctor Payments Data

Hee Oh, MD

Internal Medicine · West Covina, CANPI 1225106693

Payments from drug & device makers

$5,016in general payments, 2019–2025

Across 148 payments — averaging $33.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$645
  • AbbVie$423
  • Amarin Pharma, Inc.$308
  • Amgen$196
  • Nestle Healthcare Nutrition Inc.$149
  • plus $812 from 9 others

What the payments were for

  • Food & beverage$5,010100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,016 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$110,943
Medicare patients
101
Services billed
1,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase63$75,180
FarxigaDapagliflozin Propanediol65$63,616
VascepaIcosapent Ethyl51$34,017
JardianceEmpagliflozin26$30,676
Xigduo XrDapaglifloz Propaned/Metformin25$21,390
JanuviaSitagliptin Phosphate27$21,091
GlyxambiEmpagliflozin/Linagliptin19$14,746
JanumetSitagliptin Phos/Metformin Hcl18$12,205
MyrbetriqMirabegron24$10,774
BrilintaTicagrelor12$10,675
XareltoRivaroxaban17$9,238
RestasisCyclosporine12$7,613
LinzessLinaclotide13$6,638
Icosapent Ethyl15$6,386
Celecoxib55$3,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Restasis, Linzess$423$89,43188 claims
AstraZenecaFarxiga, Brilinta$2,481$74,29077 claims
Boehringer IngelheimJardiance, Glyxambi$98$45,42245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in West Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →